- Non-Immunocompromised, No History of COVID-19 Vaccination
- Non-Immunocompromised, Any History of COVID-19 Vaccination
- Immunocompromised, No History of COVID-19 Vaccination
- Immunocompromised, Any History of COVID-19 Vaccination
Dosing Schedule: Non-Immunocompromised, No History of COVID-19 Vaccination
|
Age Group |
Product |
Dose 1 |
Dose 2 |
Dose 3 |
|
6 months – 4 years |
Moderna (bivalent) |
0.25mL/25mcg |
0.25mL/25mcg |
(none) |
|
Pfizer-BioNTech (bivalent) |
0.2mL/3mcg |
0.2mL/3mcg |
0.2mL/3mcg |
|
|
5 years |
Moderna (bivalent) |
0.25mL/25mcg |
0.25mL/25mcg |
(none) |
|
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
(none) |
(none) |
|
|
6 – 11 years |
Moderna (bivalent) |
0.25mL/25mcg |
(none) |
(none) |
|
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
(none) |
(none) |
|
|
12 – 64 years* |
Moderna (bivalent) |
0.5mL/50mcg |
(none) |
(none) |
|
Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
(none) |
(none) |
|
|
65 years and up* |
Moderna (bivalent) |
0.5mL/50mcg |
0.5mL/50mcg (optional) |
(none) |
|
Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
0.3mL/30mcg (optional) |
(none) |
* The monovalent Novavax COVID-19 vaccine remains authorized for the following scenarios:
- Novavax can be used as a two-dose primary series for individuals 12+ years old. The second of the two doses should be administered 3-8 weeks after the first dose. An 8-week interval between the first and second primary series doses might be optimal for some people ages 6 months–64 years, especially for males 12–39 years old.
- Novavax can still be used as a booster dose, administered at least 6 months after a primary series, to people 18+ years old, who:
- Have already completed a COVID-19 vaccine primary series;
- Have not received any other booster dose(s); AND
- Are unable or unwilling to receive an mRNA vaccine and would not otherwise receive a booster dose.
Dosing Schedule: Non-Immunocompromised, Any History of COVID-19 Vaccination
|
Age Group |
Vaccination History |
Product |
Dose 1 |
Dose 2 |
|
6 months – 4 years |
1 dose monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
(none) |
|
2 doses monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.2mL/10mcg |
(none) |
|
|
1 dose monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/3mcg |
0.2mL/3mcg |
|
|
2 or 3 doses monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/3mcg |
(none) |
|
|
At least 2 doses of monovalent Moderna or Pfizer-BioNTech, AND at least 1 dose bivalent Moderna or Pfizer-BioNTech |
(none) |
(none) |
(none) |
|
|
5 years |
1 dose monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
(none) |
|
(or) Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
(none) |
||
|
2 doses monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.2mL/10mcg |
(none) |
|
|
(or) Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
(none) |
||
|
1 or more doses monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
(none) |
|
|
Ever received at least 1 dose bivalent Moderna or Pfizer-BioNTech |
(none) |
(none) |
(none) |
|
|
6 – 11 years |
1 or more doses monovalent Moderna or Pfizer-BioNTech, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
(none) |
|
(or) Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
(none) |
||
|
Ever received at least 1 dose bivalent Moderna or Pfizer-BioNTech |
(none) |
(none) |
(none) |
|
|
12 – 64 years* |
1 or more doses monovalent Moderna or Pfizer-BioNTech, with no bivalent doses |
Moderna (bivalent) |
0.5mL/50mcg |
(none) |
|
(or) Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
(none) |
||
|
Ever received at least 1 dose bivalent Moderna or Pfizer-BioNTech |
(none) |
(none) |
(none) |
|
|
65+ years* |
1 or more doses monovalent Moderna or Pfizer-BioNTech, with no bivalent doses |
Moderna (bivalent) |
0.5mL/50mcg |
0.5mL/50mcg |
|
(or) Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
0.3mL/30mcg |
||
|
Received only 1 dose bivalent Moderna or Pfizer-BioNTech |
Moderna (bivalent) |
0.5mL/50mcg
minimum 4-week |
(none) |
|
|
(or) Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
(none) |
||
|
Received 2 doses of bivalent Moderna or Pfizer-BioNTech |
(none) |
(none) |
(none) |
* The monovalent Novavax COVID-19 vaccine authorized for the following scenarios:
- Novavax can be used as a two-dose primary series for individuals 12+ years old. The second of the two doses should be administered 3-8 weeks after the first dose. An 8-week interval between the first and second primary series doses might be optimal for some people ages 6 months–64 years, especially for males 12–39 years old.
- Novavax can still be used as a booster dose, administered at least 6 months after a primary series, to people 18+ years old, who:
- Have already completed a COVID-19 vaccine primary series;
- Have not received any other booster dose(s); AND
- Are unable or unwilling to receive an mRNA vaccine and would not otherwise receive a booster dose.
Dosing Schedule: Immunocompromised, No History of COVID-19 Vaccination
|
Age Group |
Product |
Dose 1 |
Dose 2 |
Dose 3 |
Dose 4* |
| 6 months –4 years | Moderna (bivalent) | 0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
| Pfizer-BioNTech (bivalent) | 0.2mL/3mcg |
0.2mL/3mcg |
0.2mL/3mcg |
0.2mL/3mcg |
|
| 5 years | Moderna (bivalent) | 0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
| Pfizer-BioNTech (bivalent) | 0.2mL/10mcg |
0.2mL/10mcg |
0.2mL/10mcg |
0.2mL/10mcg |
|
| 6 – 11 years | Moderna (bivalent) | 0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
| Pfizer-BioNTech (bivalent) | 0.2mL/10mcg |
0.2mL/10mcg |
0.2mL/10mcg |
0.2mL/10mcg |
|
| 12 years and up* | Moderna (bivalent) | 0.5mL/50mcg |
0.5mL/50mcg |
0.5mL/50mcg |
0.5mL/50mcg |
| Pfizer-BioNTech (bivalent) | 0.3mL/30mcg |
0.3mL/30mcg |
0.3mL/30mcg |
0.3mL/30mcg |
* For moderately to severely immunocompromised individuals, further additional dose(s) may be administered based on clinical judgment of a health care provider and personal preference/circumstances. Any further doses should be administered at least 2 months following the most recent COVID-19 vaccine dose. Where possible, the additional dose(s) should be homologous (should match) with previous doses given.
Dosing Schedule: Immunocompromised, Any History of COVID-19 Vaccination
|
Age Group |
Vaccination History |
Product |
Dose 1 |
Dose 2 |
Dose 3 |
|
6 months – 4 years |
1 dose monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
|
2 or more doses monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
|
|
|
3 doses of monovalent Moderna, with no bivalent doses |
Moderna (bivalent) or |
0.25mL/25mcg |
0.25mL/25mcg |
|
|
|
1 dose monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/3mcg |
0.2mL/3mcg |
0.2mL/3mcg |
|
|
2 doses monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/3mcg |
0.2mL/3mcg |
|
|
|
3 doses of Pfizer-BioNTech, with no bivalent doses |
Pfizer (bivalent) |
0.2mL/3mcg |
0.2mL/3mcg |
|
|
|
Ever received at least 1 bivalent dose of Moderna or Pfizer-BioNTech |
Moderna (bivalent) or |
0.25mL/25mcg |
|
|
|
|
Pfizer (bivalent) |
0.2mL/3mcg |
|
|
||
|
5 years |
1 dose monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
|
2 doses monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
0.25mL/25mcg |
|
|
|
3 doses monovalent Moderna, with no bivalent doses |
Moderna (bivalent) or |
0.25mL/25mcg |
0.25mL/25mcg |
|
|
|
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
|
||
|
1 dose monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
0.2mL/10mcg |
|
|
2 doses monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
|
|
|
3 doses monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
|
|
|
Ever received at least 1 dose bivalent Moderna or Pfizer-BioNTech |
Moderna (bivalent) or |
0.25mL/25mcg |
|
|
|
|
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
|
|
||
|
6-11 years |
1 dose monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
0.25mL/25mcg |
0.25mL/25mcg |
|
2 doses monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.25mL/25mcg |
0.25mL/25mcg |
|
|
|
1 dose monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
0.2mL/10mcg |
|
|
2 doses monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
|
|
|
3 doses monovalent Moderna or 3 doses monovalent Pfizer-BioNTech, with no bivalent doses |
Moderna (bivalent) or |
0.25mL/25mcg |
0.25mL/25mcg |
|
|
|
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
0.2mL/10mcg |
|
||
|
Ever received at least 1 dose bivalent Moderna or Pfizer-BioNTech |
Moderna (bivalent) or |
0.25mL/25mcg |
|
|
|
|
Pfizer-BioNTech (bivalent) |
0.2mL/10mcg |
|
|
||
|
12 years and up** |
1 dose monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.5mL/50mcg |
0.5mL/50mcg |
0.5mL/50mcg |
|
2 doses monovalent Moderna, with no bivalent doses |
Moderna (bivalent) |
0.5mL/50mcg |
0.5mL/50mcg |
|
|
|
1 dose monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
0.3mL/30mcg |
0.3mL/30mcg |
|
|
2 doses monovalent Pfizer-BioNTech, with no bivalent doses |
Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
0.3mL/30mcg |
|
|
|
At least 3 doses of monovalent Moderna or Pfizer-BioNTech, with no bivalent doses |
Moderna (bivalent) or |
0.5mL/50mcg |
0.5mL/50mcg |
|
|
|
Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
0.3mL/30mcg |
|
||
|
Ever received at least 1 dose bivalent Moderna or Pfizer-BioNTech |
Moderna (bivalent) or |
0.5mL/50mcg |
|
|
|
|
Pfizer-BioNTech (bivalent) |
0.3mL/30mcg |
|
|
* For moderately to severely immunocompromised individuals, further additional dose(s) may be administered based on clinical judgment of a health care provider and personal preference/circumstances. Any further doses should be administered at least 2 months following the most recent COVID-19 vaccine dose. Where possible, the additional dose(s) should be homologous (should match) with previous doses given.
** The monovalent Novavax COVID-19 vaccine remains authorized for the following scenarios:
- Novavax can be used as a two-dose primary series for individuals 12+ years old. The second of the two doses should be administered 3-8 weeks after the first dose. An 8-week interval between the first and second primary series doses might be optimal for some people ages 6 months–64 years, especially for males 12–39 years old.
- People aged 12 years and up who previously received one or more doses of Novavax COVID-19 vaccine are recommended to receive one bivalent mRNA vaccine dose at least 8 weeks after their last monovalent dose.
- Otherwise, Novavax can still be used as a booster dose, administered at least 6 months after a primary series, to people 18+ years old, who:
- Have already completed a COVID-19 vaccine primary series,
- Have not received any other booster dose(s); AND
- Are unable or unwilling to receive an mRNA vaccine and would not otherwise receive a booster dose.